Today's Headlines From "The Pink Sheet" DAILY - Amgen, GSK, Lilly, Sanofi And More

Amgen, GSK To Team Up On Denosumab Commercialization in Europe

Amgen's big bet on denosumab gets a boost from a Big Pharma partner in Europe, with U.S. rights intact.

 

Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch

Bristol/Sanofi blockbuster label was quietly updated two months ago to include precautionary statement and pharmacogenomic data about non-responders to Plavix. That label dovetails with Lilly's initial positioning of prasugrel.

 

Standing Alone While Standing Together: A Conversation With Millennium CEO Dunsire (Pt. 2 Of 2)

Dunsire talks about what it takes for Millennium, Takeda's Oncology program, to operate a a stand-alone unit within the Japanese pharma, and strategies to retain key staff and culture.

 

FDA, Boehringer Disagree On Non-Inferiority Margin For Micardis Prophylaxis

Agency will tell advisory committee that non-inferiority analysis should account for improvements in standard of care that change effect size.

 

Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets

Shantha's pipeline includes Rotavirus, conjugated typhoid and HPV vaccines.

 

FDA Giving King's CorVue A Chance Despite Failed Trials

Cardio-renal advisory committee will review King's CorVue efficacy data from studies that departed from FDA's development guidance.

 

Not a subscriber? Sign-up for a free trial to "The Pink Sheet" DAILY today.